ceralifimod (ONO 4641) - Ono Pharma
Q2 2012 Results (Merck Serono) - Aug 15, 2012 - Anticipated decision on initiation of P3 trial for MS in 2013 
Anticipated new P3 trial • Anticipated phase shift Immunology • Multiple Sclerosis
http://www.larvolonline.com/tlg/ccdb/MerckSeronoQ2'12ResultsPresentationAug152012.pdf
 
Aug 15, 2012
 
(IR8)
 
b586e543-88d7-495d-af3d-eda8b3e51711.jpg